Due to its key role in regulating anti-cancer immune responses, positive modulation of the cGAS-STING pathway signaling has been proposed as a potential therapeutic strategy to enhance tumor immunogenicity and sensitivity to a variety of immunotherapies, such as, cancer vaccine and immune checkpoint blockade [127]. The gene discussed is STING1; the disease is neoplasm.